2012 Annual Report R&D PIPELINE OuR PIPElINE IS ONE OF THE STRONGEST IN THE INDuSTRy. 10 Bristol-Myers Squibb  Exploratory Development Nivolumab (Anti-PD-1) Elotuzumab Metreleptin Peginterferon lambda-1a Daclatasvir (NS5A Inhibitor) Asunaprevir (NS3 Inhibitor) Oncology Metabolic  Diseases Cardiovascular Virology Neuroscience Immunoscience Full Development Ongoing Development for Approved Medicines ** Anti-Fucosyl GM1 JAK2 Inhibitor IL-21 lirilumab (Anti-KIR) urelumab (Anti-CD137) Notch Inhibitors Anti-CXCR4 Anti-lAG3 GPR119 Agonist PEG-FGF21 GPR40 Agonist 11 β HSD Inhibitor LXR Modulators PCSK9 Adnectin IKur Antagonists PEG-Relaxin CCR2/5 Antagonists  Factor XIa Inhibitor (Parenteral)  Factor XIa Inhibitor (Oral) Anti-PD-L1 HIV Maturation Inhibitor NS5B Non Nuc Inhibitor HIV Attachment Inhibitor NRT Inhibitor Microtubule Stabilizer Triple Reuptake Inhibitors  Gamma Secretase Modulator α -7 Nicotinic Agonist Myostatin Adnectin Anti-CD40L Anti-CD40 Anti-CD28 Anti-Il31  Il-17/Il-23 biAb S1P1 Modulator CCR1 Antagonists LPA1 Antagonist Anti-IP10 Clazakizumab (Anti-Il6) Yervoy 1st line Metastatic Melanoma  Adjuvant Melanoma  1st line  Squamous  Non-Small Cell Lung  Small Cell Lung  Prostate (post hormonal therapy)  Prostate (post chemotherapy)  Gastric  Ovarian Sprycel  Pediatric  Pancreatic Erbitux Esophageal Forxiga*  Fixed dose with metformin  Fixed dose with  Onglyza Pediatric Onglyza Pediatric  Cardiovascular Outcomes Bydureon   Dual-Chamber Pen  Weekly Suspension  Cardiovascular Outcomes  Pediatric Byetta Pediatric Eliquis Venous Thromboembolism Treatment Baraclude  Pediatric Reyataz Pediatric Powder Sustiva  Pediatric Orencia Lupus Nephritis  Psoriatic Arthritis Compounds in  Exploratory Development  are in preclinical or  early clinical development.  Full Development  compounds are  investigational drugs that are in later-stage clinical development  or have been submitted to regulatory agencies for approval. The  Ongoing Development  for  Approved Medicines  table  includes compounds that have been approved in at least  one major market and are in development for additional  indications or formulations that may benefit patients. ** Includes Phase II or later  registrational programs  *  Forxiga  is not approved in the U.S. Pipeline data as of February 15, 2013